On November 5, 4,142 foreign companies will open booths at the National Exhibition and Convention Center in Shanghai, the largest foreign exhibitor count in the nine-year history of the China International Import Expo. The hall will be full of scanners, surgical robots and lab platforms. The more useful signal for anyone hiring in this industry, though, is not on the floor. It is in the announcement pages of Chinese listed companies, where more than a dozen pharmaceutical and medical-device firms have replaced chairmen, presidents or chief executives inside a two-month window.

That is a lot of churn for one quarter. And the replacements share a pattern that matters more than the departures.

The job description changed before the job did

Look at who is stepping up. Fosun Pharma promoted Wang Xingli to president in July. He is a clinician by training, joined from Novartis in 2023, and moved through the commercial side of the business before taking the top operating seat. China National Pharmaceutical Group’s listed arm, Guoyao Xiandai, elected Feng Jun as chairman in August; his career started in a research institute, not a sales region. Xiansheng Pharmaceutical went further and handed the CEO title back to its founder, Ren Jinsheng, while moving Zhou Yunshu — who had held the seat for less than six months — into the president role.

Read those three moves together and the direction is clear. The credential that gets a candidate into the final round in 2026 is not “twenty years of hospital coverage.” It is “can you defend a pipeline.”

Xiansheng’s own numbers explain why. In the first half of 2026 the company booked RMB 4.58 billion in revenue, up 27.8% year on year, with net profit of RMB 830 million, up 37.9%. Innovative drugs contributed RMB 3.89 billion of that revenue — 84.9% of the total, spread across ten approved products in neuroscience, oncology, immunology and anti-infectives. When four-fifths of your revenue comes from products you developed, the person running the company has to be able to argue about clinical endpoints with a chief medical officer and about pricing with a reimbursement committee. Neither conversation rewards a channel background.

Fosun shows the same shift from a different angle. Revenue in the first half reached RMB 20.44 billion, up 4.75%, with net profit essentially flat at RMB 1.72 billion. That is a company that needs a new growth engine, not better distribution. Putting a physician-executive in the president’s chair is a statement about what the next five years are supposed to be made of.

What this does to a search

I have written before that China’s pharma hiring problem is a supply problem. This quarter forces a correction: it is a profile problem. The supply of senior commercial leaders is deep. The supply of people who can hold a clinical development argument, a reimbursement negotiation and a P&L at the same time is thin, and the boards now competing for them are not only the obvious giants.

Three practical consequences for anyone building a leadership team here.

First, the spec has to be written around portfolio stage, not seniority. A company with two assets in Phase III and nothing on market needs a different president than a company with ten marketed products and a patent cliff. Writing “15+ years in pharma, proven P&L” gets you a shortlist of commercial operators who will be judged on the wrong metrics in year one.

Second, budget the search cycle honestly. Dual-profile candidates — clinical or medical degree plus commercial ownership — are typically in role, under non-compete, and not answering inbound messages. A mandate of that shape runs four to six months in Shanghai or Suzhou, and longer if the role sits in Chengdu or Wuhan where the candidate pool is smaller and relocation is the real objection.

Third, internal succession needs a runway, not a title. The companies that handled this well moved high-potentials through medical affairs or clinical development for 18 months before the GM conversation. The ones that struggled promoted a strong sales director into a product-driven job and discovered the gap in the second board meeting.

Pay is not the binding constraint at the top. Wantai Biological disclosed pre-tax pay of RMB 3.2416 million for its general manager in its 2025 annual report — the highest figure among its executives — against a backdrop of three consecutive years of falling profit in its HPV vaccine business. Money moved; the business did not. That is the clearest argument that compensation alone does not fix a profile mismatch, and the clearest argument for paying properly when the profile is right.

The multinational version is not identical

Foreign companies are reshuffling too, but for a different reason. Thermo Fisher named Dan Rosen president of its China business on August 18. Aspen Pharmacare’s China general manager left on August 14, roughly fifteen months after arriving. BD, Novo Nordisk, Takeda and Boehringer Ingelheim have all moved China leadership in the past two quarters.

The old MNC playbook was to send a trusted executive from headquarters. That playbook assumed China was a growth market where execution was the only variable. It is now also a source of products, which means the China head has to read clinical data, understand the local approval calendar, and negotiate with domestic partners who have their own pipelines. The profile MNCs are hiring for in 2026 looks more local than it did in 2020, and more technical than it did in 2018.

One caveat, and it cuts against the tidy story above. Not every replacement is a strategic upgrade. Some are boards buying time, and a founder returning as CEO can mean the professional-manager experiment failed rather than that the strategy sharpened. The distinguishing test is whether the new leader’s first twelve months produce portfolio decisions — discontinuations, licensing moves, capacity commitments — or just a reorganisation chart. If it is the latter, the next search starts sooner than anyone expects.

Where the mandates actually sit

What SunTzu Recruit sees in live mandates tracks the pattern. Demand is concentrated in greater China commercial leadership for companies with China-developed assets, in medical affairs and market access leads who can carry a product through hospital listing and reimbursement, and in CMC and clinical operations directors who keep timelines intact. Cities matter: Shanghai for commercial and clinical leadership, Suzhou and Hangzhou for development and manufacturing, Chengdu and Wuhan for growing domestic players who cannot yet pay Shanghai packages but can offer scope.

The candidates who clear these processes are rarely the ones with the cleanest CV. They are the ones who can explain, in specific terms, why a trial design was changed, what a reimbursement negotiation actually cost, and which product they killed.

The CIIE floor next week will be about products. The hiring market behind it is about who is allowed to decide which products survive. SunTzu Recruit’s own mandate flow says the same thing in a cruder form: fewer roles, longer shortlists, higher cost of a wrong hire. That decision now sits with a smaller group of people than it did two years ago, and the search for them has become the harder half of the job.

Sources: Jiemian News (October 2026, executive changes at Chinese and multinational pharma companies), Fosun Pharma and Xiansheng Pharmaceutical 2026 interim results, Wantai Biological 2025 annual report, CCTV (October 29, 2026, ninth CIIE exhibitor figures), company announcements (August–October 2026).